Patents by Inventor Hasnain Ahmed Malik

Hasnain Ahmed Malik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolopyridine derivatives and uses thereof
    Patent number: 11787785
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 17, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Y F Ting
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20230279394
    Abstract: The present invention is directed to compositions and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: December 16, 2020
    Publication date: September 7, 2023
    Inventors: Muluken BELEW, Simone BONAZZI, James BRADNER, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Carsten RUSS, Frederic SIGOILLOT, Susan C. STEVENSON, Noel Marie-France THOMSEN, Pamela TING
  • Pyrazolopyridine Derivatives and Uses thereof
    Publication number: 20230108325
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: March 14, 2022
    Publication date: April 6, 2023
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela YF TING
  • 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20230067476
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 2, 2023
    Inventors: Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
  • 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11566022
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders, including hemoglobinopathies, sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Dales, John Ryan Kerrigan, Philip Lam, Hasnain Ahmed Malik, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Ting
  • 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof
    Publication number: 20220402904
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: December 16, 2020
    Publication date: December 22, 2022
    Inventors: Simone BONAZZI, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Gary O'BRIEN, Andrew W. PATTERSON, Noel Marie-France THOMSEN, Pamela TING
  • GLUE DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease
    Publication number: 20220033407
    Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: December 13, 2019
    Publication date: February 3, 2022
    Inventors: Mihai D. Azimioara, Bei Chen, Robert Epple, Declan Hardy, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Fabio Meier, Truc Ngoc Nguyen, Barun Okram, Sejal Patel, Rodrigo Rodriguez, Duncan Shaw, Yiping Shen, Baogen WU
  • 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11192877
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: December 7, 2021
    Assignee: Novartis AG
    Inventors: Claire Adcock, Simone Bonazzi, Artiom Cernijenko, Philip Lam, Kathryn Taylor Linkens, Hasnain Ahmed Malik, Noel Marie-France Thomsen, Michael Scott Visser
  • N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
    Patent number: 11066369
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: July 20, 2021
    Assignee: Novartis AG
    Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, True Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
  • 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20200017461
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 16, 2020
    Inventors: Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
  • N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease
    Publication number: 20200002281
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: September 10, 2019
    Publication date: January 2, 2020
    Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, Truc Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
  • N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
    Patent number: 10450273
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Novartis AG
    Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, Truc Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu